1. Bloem BR, Okun MS, Klein C. Parkinson’s disease. Lancet Neurology. 2021;397(10291):2284-2303.
2. Postuma RB, Berg D, Stern M, et al. MDS clinical diagnostic criteria for Parkinson’s disease. Movement Disorders. 2015;30(12):1591-1601.
3. Martinez-Martin P, Rodriguez-Blazquez C, Kurtiz MM, et al. The impact of non-motor symptoms on health-related quality of life of patients with Parkinson’s disease. Mov Disord. 2011;26(3):399-406.
4. Langston WJ. The Parkinson’s complex: parkinsonism is just the tip of the iceberg. Ann Neurol. 2006;59(4):591-596.
5. Cong S, Xiang C, Zhang S, et al. Prevalence and clinical aspects of depression in Parkinson’s disease: a systematic review and meta‑analysis of 129 studies. Neurosci Biobehav Rev. 2022;141:104749. doi:10.1016/j.neubiorev.2022.104749
6. Reijnders JS, Ehrt U, Weber WE, et al. A systematic review of prevalence studies in depression in Parkinson’s disease. Mov Disord. 2008;23(2):183-189.
7. Zahodne LB, Marsiske M, Okun MS, et al. Components of depression in Parkinson disease. J Geriatr Psychiatry Neurol. 2012;25(3):131-137.
8. Skapinakis P, Bakola E, Salanti G, et al. Efficacy and acceptability of selective serotonin reuptake inhibitors for the treatment of depression in Parkinson’s disease: a systematic review and meta-analysis of randomized controlled trials. BMC Neurology. 2010;10:49. doi:10.1186/1471-2377-10-49
9. Richard IH, McDermott MP, Kurlan R, et al; SAD-PD Study Group. A randomized, double-blind placebo-controlled trial of antidepressants in Parkinson’s disease. Neurology. 2012;78(16):1229-1236.
10. Takahashi M, Tabu H, Ozaki A, et al. Antidepressants for depression, apathy, and gait instability in Parkinson’s disease: a multicenter randomized study. Intern Med. 2019;58(3):361-368.
11. Bonuccelli U, Mecco G, Fabrini G, et al. A non-comparative assessment of tolerability and efficacy of duloxetine in the treatment of depressed patients with Parkinson’s disease. Expert Opin Pharmacother. 2012;13(16):2269-2280.
12. Wantanabe N, Omorio IM, Nakagawa A, et al; MANGA (Meta-Analysis of New Generation Antidepressants) Study Group. Safety reporting and adverse-event profile of mirtazapine described in randomized controlled trials in comparison with other classes of antidepressants in the acute-phase treatment of adults with depression. CNS Drugs. 2010;24(1):35-53.
13. Barone P, Scarzella L, Marconi R, et al; Depression/Parkinson Italian Study Group. Pramipexole versus sertraline in the treatment of depression in Parkinson’s disease: a national multicenter parallel-group randomized study. J Neurol. 2006;253(5):601-607.
14. Smith KM, Eyal E, Weintraub D, et al; ADAGIO Investigators. Combined rasagiline and anti-depressant use in Parkinson’s disease in the ADAGIO study: effects on non-motor symptoms and tolerability. JAMA Neurology. 2015;72(1):88-95.
15. Seppi K, Chaudhuri R, Coelho M, et al; the collaborators of the Parkinson’s Disease Update on Non-Motor Symptoms Study Group on behalf of the Movement Disorders Society Evidence-Based Medicine Committee. Update on treatments for nonmotor symptoms of Parkinson’s disease--an evidence-based medicine review. Mov Disord. 2019;34(2):180-198.
16. Kwok JYY, Kwan JCY, Auyeung M, et al. Effects of mindfulness yoga vs stretching and resistance training exercises on anxiety and depression for people with Parkinson disease: a randomized clinical trial. JAMA Neurol. 2019;76(7):755-763.
17. De Waele S, Cras P, Crosiers D. Apathy in Parkinson’s disease: defining the Park apathy subtype. Brain Sci. 2022;12(7):923.
18. Mele B, Van S, Holroyd-Leduc J, et al. Diagnosis, treatment and management of apathy in Parkinson’s disease: a scoping review. BMJ Open. 2020;10(9):037632. doi:10.1136/bmjopen-2020-037632
19. Mele B, Ismail Z, Goodarzi Z, et al. Non-pharmacological interventions to treat apathy in Parkinson’s disease: a realist review. Clin Park Relat Disord. 2021;4:100096. doi:10.1016/j.prdoa.2021.100096
20. Chung SJ, Asgharnejad M, Bauer L, et al. Evaluation of rotigotine transdermal patch for the treatment of depressive symptoms in patients with Parkinson’s disease. Expert Opin Pharmacother. 2016;(17)11:1453-1461.
21. Goldman JG, Guerra CM. Treatment of nonmotor symptoms associated with Parkinson disease. Neurol Clin. 2020;38(2):269-292.
22. Schneider RB, Auinger P, Tarolli CG, et al. A trial of buspirone for anxiety in Parkinson’s disease: safety and tolerability. Parkinsonism Relat Disord. 2020;81:69-74.
23. Moonen AJH, Mulders AEP, Defebvre L, et al. Cognitive behavioral therapy for anxiety in Parkinson’s disease: a randomized controlled trial. Mov Disord. 2021;36(11):2539-2548.
24. Shulman LM, Singer C, Bean JA, et al. Internal tremor in patient with Parkinson’s disease. Mov Disord. 1996;11(1):3-7.
25. Cochrane GD, Rizvi S, Abrantes A, et al. Internal tremor in Parkinson’s disease, multiple sclerosis, and essential tremor. Parkinsonism Relat Disord. 2015;21(10):1145-1147.
26. Del Prete E, Schmitt E, Meoni S, et al. Do neuropsychiatric fluctuations temporally match motor fluctuations in Parkinson’s disease? Neurol Sci. 2022;43(6):3641-3647.
27. Kleiner G, Fernandez HH, Chou KL, et al. Non-motor fluctuations in Parkinson’s disease: validation of the non-motor fluctuation assessment questionnaire. Mov Disord. 2021;36(6):1392-1400.
28. Pachi I, Maraki MI, Giagkou N, et al. Late life psychotic features in prodromal Parkinson’s disease. Parkinsonism Relat Disord. 2021;86:67-73.
29. Forsaa EB, Larsen JP, Wentzel-Larsen T, et al. A 12-year population-based study of psychosis in Parkinson’s disease. Arch Neurol. 2010;67(8):996-1001.
30. Chang A, Fox SH. Psychosis in Parkinson’s disease: epidemiology, pathophysiology, and management. Drugs. 2016;76(11):1093-1118.
31. Kasunich A, Kilbane C, Wiggins R. Movement disorders moment: pain and palliative care in movement disorders. Practical Neurology. 2021;20(4):63-67.
32. Burn D, Emre M, McKeith I, et al. Effects of rivastigmine in patients with and without visual hallucinations in dementia associated with Parkinson’s disease. Mov Disord. 2006;21(11):1899-1907.
33. Tripathi M, Vibha D. Reversible dementias. Indian J Psychiatry. 2009; 51 Suppl 1(Suppl 1): S52-S55.
34. Dalrymple-Alford JC, MacAskill MR, Nakas CT, et al. The MoCA: well-suited screen for cognitive impairment in Parkinson disease. Neurology. 2010;75(19):1717-1725.
35. Goldman J, Sieg, E. Cognitive impairment and dementia in Parkinson disease. Clin Geriatr Med. 2020;36(2):365-377.
36. Gonzalez-Latapi P, Bayram E, Litvan I, et al. Cognitive impairment in Parkinson’s disease: epidemiology, clinical profile, protective and risk factors. Behav Sci (Basel). 2021;11(5):74.
37. Litvan I, Goldman JG, Tröster AI, et al. Diagnostic criteria for mild cognitive impairment in Parkinson’s disease: Movement Disorder Society Task Force Guidelines. Mov Disord. 2012;27(3):349-356.
38. Dubois B, Burn D, Goetz C, et al. Diagnostic procedures for Parkinson’s disease dementia: recommendations from the movement disorder society task force. Mov Disord. 2007;22(16):2314-2324.
39. Aarsland D, Batzu L, Halliday GM, et al. Parkinson disease-associated cognitive impairment. Nat Rev Dis Primers. 2021;7(1):47. doi:10.1038/s41572-021-00280-3
40. Weintraub D, Claassen DO. Impulse control and related disorders in Parkinson’s disease. Int Rev Neurobiol. 2017;133:679-717.
41. Vilas D, Pont-Sunyer C, Tolosa E. Impulse control disorders in Parkinson’s disease. Parkinsonism Relat Disord. 2012;18 Suppl 1:S80-S84.
42. Weintraub D, Koester J, Potenza MN, et al. Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients. Arch Neurol. 2010;67(5):589-595.
43. Faouzi J, Corvol JC, Mariani LL. Impulse control disorders and related behaviors in Parkinson’s disease: risk factors, clinical and genetic aspects, and management. Curr Opin Neurol. 2021;34(4):547-555.
44. Samuel M, Rodriguez-Oroz M, Antonini A, et al. Impulse control disorders in Parkinson’s disease: management, controversies, and potential approaches. Mov Disord. 2015;30(2):150-159.
45. Frank MJ, Samanta J, Moustafa AA, et al. Hold your horses: impulsivity, deep brain stimulation and medication in Parkinsonism. Science. 2007;318(5854):1309-1312.
46. Jahanshahi M, Obeso I, Baunez C, et al. Parkinson’s disease, the subthalamic nucleus, inhibition, and impulsivity. Mov Disord. 2015;30(2):128-140.
47. Castrioto A, Lhommée E, Moro E, et al. Mood and behavioral effects of subthalamic stimulation in Parkinson’s disease. Lancet Neurol. 2014;13(3):287-305.
